Actinium Pharmaceuticals Strengthens Board with New Appointment
Company Announcements

Actinium Pharmaceuticals Strengthens Board with New Appointment

Actinium Pharmaceuticals ( (ATNM) ) has issued an update.

Actinium Pharmaceuticals has appointed Dr. June Almenoff, a seasoned biopharma executive with over 25 years of experience in drug development and leadership, to its Board of Directors. Dr. Almenoff’s extensive background in translational medicine and business development, including leading successful product approvals, is expected to bolster Actinium’s strategic vision and innovation in targeted radiotherapies. Her expertise will be invaluable as Actinium aims to enhance its position in the radiopharmaceutical sector, focusing on innovative treatments for oncology patients.

Find detailed analytics on ATNM stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyActinium Pharmaceuticals: Phase 3 SIERRA results of Iomab-B published in JCO
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App